Mechanisms of Action of Interleukin-2 Superkines

点击翻译按钮获取中文摘要

Immunotherapy is emerging as one of the largest breakthroughs in cancer therapy in the last 30 years, due to the recent approval of the antibody therapeutics Ipilimumab (anti-CTLA4) and Pembrolizumab (anti-PD-1). This has greatly increased interest in other immune activating modalities, either for monotherapy, or in combination with antibody therapy. Here we propose to decipher molecular mechanisms that underpin the biological function of a new class of immune activating drugs (IL-2 superkines).